SUPRIYA LIFESCIENCE LTD

During the earnings call for Q1 FY '27, management reported a revenue of Rs. 190 crores, marking a 31% year-on-year growth, despite a sales deferment of approximately Rs. 35 crores due to water shortages. EBITDA was reported at Rs. 47 crores, an 8.1% decline year-on-year, with margins at 25%. Management attributed the margin decline to temporary factors, including water scarcity and increased power costs due to a change in solar policy. Exports contributed 81% of revenue, with Asia and Europe being significant markets. The company launched two new anesthetic products and has plans for ADHD products. Management reiterated a goal of achieving Rs. 1,000 crores in revenue by FY '27 and maintaining EBITDA margins between 33% to 35%. They also discussed ongoing efforts to enhance operational efficiency and address temporary challenges, indicating confidence in future performance.

Management provided a balanced view of growth opportunities and challenges faced during the quarter.